Saturday 17 October 2026 Export LEXX’s income statement to Excel — free account

Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

2.92 0.07 −2.34%

Follow LEXX

Alert me

Market cap: $6.3M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: 4/9
Altman Z: −23.89
Beneish M: −3.56
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 6.30

Revenue 0.54

Net Income (7.74)

Free Cash Flow (7.53)

Net Debt (3.62)

Current Ratio 10.60

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.45)

P/S ratio 8.91

P/B ratio 1.11

Past 5Y EPS Growth —

This Y EPS Growth 59.09%

Next Y EPS Growth (14.81%)

Next Y revenue growth (97.17%)

Next 5Y EPS Growth 24.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.30%

10-year low 10-year high

P/B against its own 10 years 16.83%

10-year low 10-year high

EV/Sales against its own 10 years 4.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	7	2	4
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	2	8	3	4

	2023	2024	2025	Q'26
Payables	0	1	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	0	1	1	0

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.53%	40.34%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.95%	(30.14%)

Revenue $m

	Nov	May	Aug	Year
’26	—	—	—	—
’25	0	0	0	1
’24	0	0	0	0
’23	0	0	0	0
’22	0	0	0	0
’21	0	0	0	1
’20	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Nov	Feb	May	Aug	Year
’26	(1)	(2)	(2)	—	—
’25	(3)	(1)	(4)	(3)	(10)
’24	(1)	(1)	(1)	(2)	(5)
’23	(1)	(1)	(2)	(2)	(6)
’22	(1)	(1)	(1)	(1)	(5)
’21	(1)	(1)	(1)	(1)	(4)
’20	(1)	(1)	(1)	(1)	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Nov	Feb	May	Aug	Year
’26	(1)	(2)	(2)	—	—
’25	(3)	(2)	(4)	(3)	(11)
’24	(1)	(1)	(1)	(2)	(5)
’23	(1)	(1)	(2)	(2)	(6)
’22	(1)	(1)	(1)	(1)	(5)
’21	(1)	(1)	(1)	(1)	(4)
’20	(1)	(1)	(1)	(1)	(3)

Fiscal quarters ending in the months shown.

EPS $

	Nov	Feb	May	Aug	Year
’26	(1.05)	(0.90)	(1.20)	—	—
’25	(2.40)	(2.25)	(3.15)	(1.95)	(9.90)
’24	(1.95)	(0.90)	(1.95)	(2.25)	(7.05)
’23	(4.50)	(3.30)	(5.55)	(1.80)	(15.14)
’22	(5.25)	(3.75)	(6.15)	(3.60)	(18.59)
’21	(3.60)	1.35	(7.50)	(4.66)	(14.39)
’20	(5.26)	(5.62)	(7.53)	(4.50)	(22.51)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.40	8.10	22.50	10.65	5.10	6.41	27.00	9.74	18.00	6.90	Analyst estimates 2026–2028 Powerpack
	High	10.50	63.90	76.20	50.63	16.80	187.50	74.10	53.93	102.75	36.45
People
People	Employees	—	—	—	8	4	6	7	5	7	7
	Revenue/emp, $m	0.00	0.00	0.00	0.03	0.08	0.12	0.04	0.05	0.07	0.10
Income, $m
Income, $m	Revenue	0	0	0	0	0	1	0	0	0	1
	Gross margin, %	(13.51)	50.94	94.18	89.71	68.42	75.74	71.89	86.07	98.97	99.62
	EBT	(1)	(2)	(7)	(4)	(4)	(4)	(7)	(7)	(6)	(12)
	EBT margin, %	(3,138.08)	(3,033.81)	(1,525.32)	(1,868.10)	(1,317.92)	(576.19)	(2,891.03)	(2,967.51)	(1,251.07)	(1,687.41)
	Net income	(1)	0	(7)	(4)	(4)	(4)	(7)	(7)	(6)	(12)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.02	0.03	2.75	1.29	1.70	2.47	0.65	0.51	0.56	0.59
	Earnings	(0.90)	(0.95)	(41.93)	(24.07)	(22.51)	(14.39)	(18.59)	(15.14)	(7.05)	(9.90)
	Cash flow	(0.40)	(0.67)	(15.98)	(17.39)	(14.16)	(13.62)	(12.43)	(13.33)	(6.00)	(8.70)
	Capex	0.00	0.00	(0.54)	(4.45)	(0.18)	0.66	(0.46)	(0.38)	(0.23)	(0.08)
	Free cash flow	(0.40)	(0.67)	(16.52)	(21.84)	(14.34)	(12.96)	(12.89)	(13.71)	(6.23)	(8.79)
	Book value	0.16	1.53	15.15	14.41	13.42	44.60	19.45	6.07	9.27	2.17
	Shares, m	2	2	0	0	0	0	0	0	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	22.37	15.18	6.10	37.81	68.21	30.73	97.40	22.60
	P/B	0.00	0.51	4.06	1.36	0.77	2.09	2.28	2.59	5.90	6.13
	EV/Sales	0.00	0.00	18.36	9.12	2.14	21.60	44.38	24.48	83.42	19.90
	EV/FCF	0.00	0.00	(3.06)	(0.54)	(0.20)	(4.10)	(2.24)	(0.91)	(7.50)	(1.33)
Cash, $m
Cash, $m	Operating cash flow	(1)	(1)	(3)	(3)	(3)	(4)	(5)	(6)	(5)	(10)
	Capex	0	0	0	(1)	0	0	0	0	0	0
	Free cash flow	(1)	(1)	(3)	(4)	(3)	(4)	(5)	(6)	(5)	(11)
Balance, $m
Balance, $m	Working capital	0	3	2	2	2	12	7	2	7	2
	Total debt	0	0	0	—	0	0	0	0	—	—
	Net debt	0	(2)	(2)	(1)	(1)	(12)	(6)	(1)	(7)	(2)
	Shareholders’ equity	0	3	2	2	2	13	8	3	8	3
Returns, %
Returns, %	ROA	(70.90)	(659.83)	(440.85)	(162.85)	(142.97)	(50.04)	(68.90)	(122.09)	(96.98)	(182.50)
	ROIC	0.00	0.00	(568.66)	(156.74)	(209.81)	(269.29)	(281.06)	(339.63)	(325.87)	(1,168.81)
	ROE	(74.25)	(114.25)	(245.03)	(170.46)	(158.21)	(51.81)	(70.25)	(129.26)	(112.10)	(231.96)

Negative figures in brackets.

All 10 years →

Fiscal years to Aug 2025 · latest quarter Feb 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ACXP Acurx Pharmaceuticals, Inc.	$6.5M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$6.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
EVGN Evogene Ltd.	$6.3M	— (loss-making)	— (loss-making)	−35.02% (below 0%: shrinking)	n/m	+17.72% (above 0%: growing)	40.63%	(738.62%)	Compare
LEXX Lexaria Bioscience Corp.	$6.3M	— (loss-making)	— (loss-making)	−89.12% (below 0%: shrinking)	n/m	+53.90% (above 0%: growing)	100.00%	0.00%
ENVB Enveric Biosciences, Inc.	$6.2M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
TRAW Traws Pharma, Inc.	$6.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$6.3M	—	—	−21.15%	—	+7.68%	0.00%	0.00%

All 614 Biotechnology stocks →

Lexaria Bioscience Corp. (LEXX) key facts

Strength: Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024.
Lexaria Bioscience Corp. (LEXX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LEXX traded at $2.92, a market capitalization of $6.3 million.
Return on equity was −232.0% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −23.89 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.